{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:02:19Z","timestamp":1777510939969,"version":"3.51.4"},"reference-count":33,"publisher":"Media Sphere Publishing House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:p>Purpose. This study aimed to assess the economic impact of aflibercept 8 mg (114.3 mg\/ml, 0.263 ml; hereinafter aflibercept 8 mg) compared with alternative anti-VEGF agents in adult patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) over a 2-year treatment period. Material and methods. The study compared different anti-VEGF therapies (aflibercept 8 mg; aflibercept 2 mg \u2014 40 mg\/ml, 0.278 ml; brolucizumab 6 mg \u2014 120 mg\/ml, 0.23 ml; ranibizumab 0.5 mg \u2014 10 mg\/ml, 0.23 ml) from the perspective of the healthcare system of the Russian Federation over a 2-year horizon. The number of intravitreal injections was determined based on an indirect comparative analysis; the number of administrations was reconstructed using an anchor value for aflibercept 8 mg and published differences in injection frequencies. Costs were calculated using the weighted average procurement price per package. The burden on the compulsory health insurance (CHI) system was estimated based on the average cost per insurance case (Diagnosis-Related Group, DRG, for \u201cIntravitreal drug administration\u201d) of 47 459.63 RUB. Results. The costs over 2 years were lower with aflibercept 8 mg, resulting in savings of 99 713\u2014140 434 RUB per patient with nAMD and 98 305\u2014173 196 RUB with DME, depending on the comparator drug. When assessing the burden on the CHI system, savings amounted to 142 378\u2014489 783 RUB per patient with nAMD and 119 598\u2014541 039 RUB per patient with DME. Conclusion. The use of aflibercept 8 mg in nAMD and DME reduces both direct treatment costs and expenditures of the CHI system in the first and second years of therapy, as well as cumulatively over 2 years. The results remain robust under price reductions and support the economic feasibility of the use of aflibercept 8 mg.<\/jats:p>","DOI":"10.17116\/oftalma202614202140","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:38:39Z","timestamp":1777390719000},"page":"40","source":"Crossref","is-referenced-by-count":0,"title":["Cost analysis of aflibercept 8 mg versus other anti-VEGF agents"],"prefix":"10.17116","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-9242","authenticated-orcid":false,"given":"F.E.","family":"Shadrichev","sequence":"first","affiliation":[{"name":"Pavlov First Saint Petersburg State Medical University","place":["Saint Petersburg, Russia"]},{"name":"City Consultative and Diagnostic Center No. 1 \u2014 Regional Endocrinology Center","place":["Saint Petersburg, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-2903","authenticated-orcid":false,"given":"Yu.V.","family":"Strunina","sequence":"additional","affiliation":[{"name":"Association of Specialists in Health Technology Assessment","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma202614202140-1","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2019135051107"},{"key":"key-10.17116\/oftalma202614202140-2","doi-asserted-by":"publisher","DOI":"10.17816\/OV10294-109"},{"key":"key-10.17116\/oftalma202614202140-3","doi-asserted-by":"publisher","DOI":"10.17816\/OV11453-68"},{"key":"key-10.17116\/oftalma202614202140-4","unstructured":"Fayzrakhmanov RR, Zaynetdinov AF, Salavatova VF. Structure of vitreomacular interface in retinal pathology. Tochka zreniya. Vostok-Zapad. 2017;2:82-85. (In Russ.)"},{"key":"key-10.17116\/oftalma202614202140-5","doi-asserted-by":"publisher","DOI":"10.2174\/138945011794182755"},{"key":"key-10.17116\/oftalma202614202140-6","doi-asserted-by":"crossref","unstructured":"Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007;125","DOI":"10.1001\/archopht.125.9.1249"},{"key":"key-10.17116\/oftalma202614202140-7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00610.x"},{"key":"key-10.17116\/oftalma202614202140-8","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100954"},{"key":"key-10.17116\/oftalma202614202140-9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H"},{"key":"key-10.17116\/oftalma202614202140-10","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"key-10.17116\/oftalma202614202140-11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"key-10.17116\/oftalma202614202140-12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"key-10.17116\/oftalma202614202140-13","doi-asserted-by":"crossref","unstructured":"Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv Ther. 2020;37: 1173-1187","DOI":"10.1007\/s12325-020-01236-x"},{"key":"key-10.17116\/oftalma202614202140-14","doi-asserted-by":"crossref","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729-740","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"key-10.17116\/oftalma202614202140-15","doi-asserted-by":"crossref","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128:89-99","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"key-10.17116\/oftalma202614202140-16","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"key-10.17116\/oftalma202614202140-17","doi-asserted-by":"crossref","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-54","DOI":"10.1016\/j.ophtha.2014.05.006"},{"key":"key-10.17116\/oftalma202614202140-18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04414-y"},{"key":"key-10.17116\/oftalma202614202140-19","doi-asserted-by":"publisher","DOI":"10.21516\/2072-0076-2020-13-1-42-50"},{"key":"key-10.17116\/oftalma202614202140-20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-103539"},{"key":"key-10.17116\/oftalma202614202140-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.05.017"},{"key":"key-10.17116\/oftalma202614202140-22","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03312-w"},{"key":"key-10.17116\/oftalma202614202140-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.08.022"},{"key":"key-10.17116\/oftalma202614202140-24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.10.028"},{"key":"key-10.17116\/oftalma202614202140-25","unstructured":"EAEU Register of Summary of Product Characteristics. Eylea medicinal product, 114.3 mg\/ml. Electronic resource (Accessed: 26 Nov 2025). (In Russ.). https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/oftalma202614202140-26","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202514106192"},{"key":"key-10.17116\/oftalma202614202140-27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"key-10.17116\/oftalma202614202140-28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01236-x"},{"key":"key-10.17116\/oftalma202614202140-29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02577-1"},{"key":"key-10.17116\/oftalma202614202140-30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.005"},{"key":"key-10.17116\/oftalma202614202140-31","doi-asserted-by":"crossref","unstructured":"Lukic M. et al. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.Eur J Ophthalmol. SAGE Publications Ltd. 2021; 31(3): 1201-1207","DOI":"10.1177\/1120672120925034"},{"key":"key-10.17116\/oftalma202614202140-32","unstructured":"IQVIA database audits of the public pharmaceutical market segment in the Russian Federation: \u201cPublic Procurement Audit in Russia (excluding federal and regional reimbursement programs)\u201d, \u201cFederal Reimbursement Program (ONLS\/VZN)\u201d and \u201cRegional Reimbursement Program\u201d, January\u2014December 2025. IQVIA; 2026. (In Russ.)"},{"key":"key-10.17116\/oftalma202614202140-33","unstructured":"Government of the Russian Federation. Resolution No. 2188 of December 29, 2025 \u201cOn the Program of State Guarantees for Free Medical Care to Citizens for 2026 and the Planning Period of 2027\u20142028\u201d. (In Russ.). https:\/\/www.consultant.ru\/document\/cons_doc_LAW_523638"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:38:55Z","timestamp":1777390735000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2026\/2\/10042465X2026021040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,28]]}},"alternative-id":["10.17116\/oftalma202614202140"],"URL":"https:\/\/doi.org\/10.17116\/oftalma202614202140","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}